PATHILON Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Pathilon, and when can generic versions of Pathilon launch?
Pathilon is a drug marketed by Lederle and is included in two NDAs.
The generic ingredient in PATHILON is tridihexethyl chloride. Additional details are available on the tridihexethyl chloride profile page.
Summary for PATHILON
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 23 |
Patent Applications: | 945 |
DailyMed Link: | PATHILON at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for PATHILON
US Patents and Regulatory Information for PATHILON
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lederle | PATHILON | tridihexethyl chloride | INJECTABLE;INJECTION | 009729-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Lederle | PATHILON | tridihexethyl chloride | TABLET;ORAL | 009489-005 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |